-logo-1200x675.png?v=20220303080937)
The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) major shareholder Jorey Chernett bought 18,000 shares of the business's stock in a transaction that occurred on Tuesday, July 21st. The stock was purchased at an average price of $5.27 per share, for a total transaction of $94,860.00. Following the completion of the acquisition, the insider owned 10,648,858 shares in the company, valued at $56,119,481.66. This represents a 0.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Jorey Chernett also recently made the following trade(s):
- On Friday, July 10th, Jorey Chernett purchased 15,000 shares of Oncology Institute stock. The stock was acquired at an average cost of $5.85 per share, with a total value of $87,750.00.
- On Tuesday, June 23rd, Jorey Chernett purchased 18,000 shares of Oncology Institute stock. The shares were acquired at an average price of $5.02 per share, with a total value of $90,360.00.
- On Thursday, June 4th, Jorey Chernett acquired 12,000 shares of Oncology Institute stock. The shares were acquired at an average price of $4.75 per share, for a total transaction of $57,000.00.
- On Wednesday, May 20th, Jorey Chernett acquired 33,500 shares of Oncology Institute stock. The shares were acquired at an average price of $4.07 per share, for a total transaction of $136,345.00.
- On Tuesday, May 19th, Jorey Chernett acquired 5,000 shares of Oncology Institute stock. The stock was acquired at an average cost of $4.05 per share, for a total transaction of $20,250.00.
- On Tuesday, May 19th, Jorey Chernett acquired 30,000 shares of Oncology Institute stock. The shares were acquired at an average price of $4.09 per share, with a total value of $122,700.00.
Oncology Institute Price Performance
Shares of NASDAQ TOI opened at $4.95 on Wednesday. The company has a 50-day moving average price of $5.15 and a 200-day moving average price of $3.89. The stock has a market capitalization of $489.26 million, a P/E ratio of -13.38 and a beta of 0.36. The Oncology Institute, Inc. has a 1 year low of $2.32 and a 1 year high of $6.67.
Oncology Institute (NASDAQ:TOI - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The business had revenue of $147.44 million during the quarter, compared to analyst estimates of $142.10 million. As a group, equities research analysts anticipate that The Oncology Institute, Inc. will post -0.18 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on TOI. BTIG Research increased their price objective on Oncology Institute from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Thursday, July 9th. Lake Street Capital initiated coverage on Oncology Institute in a research report on Monday, July 6th. They set a "buy" rating and a $10.00 target price on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Oncology Institute in a report on Friday, July 17th. Finally, Needham & Company LLC increased their price target on Oncology Institute from $5.00 to $7.00 and gave the company a "buy" rating in a research report on Wednesday, June 17th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $8.50.
Get Our Latest Research Report on Oncology Institute
Institutional Investors Weigh In On Oncology Institute
A number of institutional investors have recently added to or reduced their stakes in TOI. LPL Financial LLC grew its position in Oncology Institute by 1.5% in the 4th quarter. LPL Financial LLC now owns 270,885 shares of the company's stock worth $964,000 after purchasing an additional 3,900 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Oncology Institute by 9.1% during the 4th quarter. AQR Capital Management LLC now owns 48,072 shares of the company's stock worth $171,000 after buying an additional 4,007 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Oncology Institute by 5.5% during the 4th quarter. HighTower Advisors LLC now owns 85,851 shares of the company's stock worth $306,000 after buying an additional 4,489 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock worth $36,000 after buying an additional 4,545 shares during the last quarter. Finally, R Squared Ltd boosted its stake in shares of Oncology Institute by 42.7% in the 1st quarter. R Squared Ltd now owns 16,353 shares of the company's stock worth $50,000 after buying an additional 4,891 shares during the last quarter. 36.86% of the stock is owned by institutional investors.
Oncology Institute Company Profile
(
Get Free Report)
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
